RS66063B1 - Jedinjenja gpr52 modulatora - Google Patents

Jedinjenja gpr52 modulatora

Info

Publication number
RS66063B1
RS66063B1 RS20241089A RSP20241089A RS66063B1 RS 66063 B1 RS66063 B1 RS 66063B1 RS 20241089 A RS20241089 A RS 20241089A RS P20241089 A RSP20241089 A RS P20241089A RS 66063 B1 RS66063 B1 RS 66063B1
Authority
RS
Serbia
Prior art keywords
fluoro
trifluoromethyl
pyridin
benzyl
pyrazole
Prior art date
Application number
RS20241089A
Other languages
English (en)
Serbian (sr)
Inventor
Sarah Joanne Bucknell
Stephen Paul Watson
Michael Alistair O'brien
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Publication of RS66063B1 publication Critical patent/RS66063B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
RS20241089A 2020-03-13 2021-03-15 Jedinjenja gpr52 modulatora RS66063B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds
EP21713103.6A EP4117784B1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
RS66063B1 true RS66063B1 (sr) 2024-11-29

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241089A RS66063B1 (sr) 2020-03-13 2021-03-15 Jedinjenja gpr52 modulatora

Country Status (23)

Country Link
US (1) US12655120B2 (enExample)
EP (1) EP4117784B1 (enExample)
JP (1) JP7492597B2 (enExample)
KR (1) KR20220152296A (enExample)
CN (1) CN115515681B (enExample)
AU (1) AU2021235257B2 (enExample)
BR (1) BR112022018287A2 (enExample)
CA (1) CA3175429A1 (enExample)
DK (1) DK4117784T3 (enExample)
ES (1) ES2992600T3 (enExample)
FI (1) FI4117784T3 (enExample)
GB (1) GB202003668D0 (enExample)
HR (1) HRP20241375T1 (enExample)
HU (1) HUE068758T2 (enExample)
IL (1) IL296413B2 (enExample)
LT (1) LT4117784T (enExample)
MX (1) MX2022011333A (enExample)
PL (1) PL4117784T3 (enExample)
PT (1) PT4117784T (enExample)
RS (1) RS66063B1 (enExample)
SI (1) SI4117784T1 (enExample)
SM (1) SMT202400402T1 (enExample)
WO (1) WO2021181122A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
EP4330232A1 (en) * 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327185A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
NZ526624A (en) 2000-12-22 2005-07-29 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
KR20100097077A (ko) 2009-02-25 2010-09-02 주식회사 중외제약 Hsp90에 대한 억제 효능을 갖는 피리디논 유도체
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
WO2017077280A1 (en) 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
CN111094278B (zh) 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
JP7425724B2 (ja) 2017-10-17 2024-01-31 エピザイム,インコーポレイティド Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
CN114650992A (zh) 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
GB202013558D0 (en) 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds

Also Published As

Publication number Publication date
IL296413B1 (en) 2025-11-01
KR20220152296A (ko) 2022-11-15
HUE068758T2 (hu) 2025-01-28
IL296413A (en) 2022-11-01
HRP20241375T1 (hr) 2024-12-20
FI4117784T3 (fi) 2024-10-10
PL4117784T3 (pl) 2025-01-13
JP2023519666A (ja) 2023-05-12
IL296413B2 (en) 2026-03-01
SMT202400402T1 (it) 2024-11-15
WO2021181122A1 (en) 2021-09-16
DK4117784T3 (da) 2024-10-14
BR112022018287A2 (pt) 2022-11-22
MX2022011333A (es) 2022-12-08
JP7492597B2 (ja) 2024-05-29
GB202003668D0 (en) 2020-04-29
CA3175429A1 (en) 2021-09-16
US12655120B2 (en) 2026-06-16
AU2021235257A1 (en) 2022-10-06
CN115515681A (zh) 2022-12-23
PT4117784T (pt) 2024-10-07
LT4117784T (lt) 2024-10-25
EP4117784B1 (en) 2024-08-28
AU2021235257B2 (en) 2026-07-16
ES2992600T3 (en) 2024-12-16
SI4117784T1 (sl) 2025-03-31
US20240254101A1 (en) 2024-08-01
EP4117784A1 (en) 2023-01-18
CN115515681B (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
JP7492597B2 (ja) Gpr52モジュレーター化合物
EP2069310B1 (en) Sulfonylpyrazoline-1-carboxamidine derivatives as 5-ht6 antagonists
EP3634956B1 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP2001505567A (ja) 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体
EP3634955A1 (en) Piperidinone formyl peptide 2 receptor agonists
JP2024522588A (ja) 抗がん化合物
IL301007A (en) GPR52 modulator compounds
EP4401833B1 (en) Gpr52 modulator compounds
CN116888115A (zh) 二氟甲基-吡啶-2-基三唑
CN112513032A (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
JP2011515359A (ja) 治療用トリアゾールアミド誘導体
CA3181583A1 (en) Methods of use for pyrimidines as ferroportin inhibitors
JP2008517994A (ja) 新規医薬品
EP2081433A2 (en) Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
RU2844473C1 (ru) Соединения модуляторы gpr52
HK40078521B (en) Gpr52 modulator compounds
HK40078521A (en) Gpr52 modulator compounds
HK40107480B (en) Gpr52 modulator compounds
HK40107480A (en) Gpr52 modulator compounds
WO2026078671A1 (en) Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists
WO2026078673A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078674A1 (en) Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025245351A1 (en) Substituted aryl sulfonamides and compositions and uses thereof
KR20140062096A (ko) Parp 억제제